Adicet bio receives fda fast track designation for lead candidate adi-001

Menlo park, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (car) t cell therapies for cancer, today announced the u.s. food and drug administration (fda) has granted fast track designation to its lead program adi-001, an investigational therapy targeting cd20 for the potential treatment of relapsed or refractory b-cell non-hodgkin's lymphoma (nhl)
ACET Ratings Summary
ACET Quant Ranking